We develop GPCR modulators for Idiopathic Pulmonary Fibrosis (IPF) and other inflammatory and metabolic conditions
About Innospera Pharma
Innospera Pharma (Montreal) is a private biotech developing small-molecule GPCR modulators for chronic and fibrotic diseases. Lead asset
ING-006, a next-generation GPR84
modulator, has shown strong anti-fibrotic activity in gold-standard preclinical models.
A 20–40x more potent analog of PBI-4050 (three Phase 2a trials; FDA-approved Phase 3 IPF protocol), ING-006 pairs a superior
pharmacological profile with an anticipated wide safety margin and tolerability.
The pipeline includes additional GPCR modulators targeting cardiometabolic and other chronic conditions.
Leadership team
Board of Directors
Pierre Laurin, BPharm, MSc
Executive Chairman and co-founder, Innospera
François Ravenelle, PhD
President and CEO, Innospera
Lyne Gagnon, PhD
CSO and co-founder, Innospera
Patricia Escoffier, PhD
Principal, Seido Capital
​
Hélène Moore, MBA
Director, Anges Québec
​
Denis Garceau, BPharm, PhD
Ex-CSO, Bellus Health
​
Hubert Sibre, LLB
Partner, Miller Thomson
​
Maxime Daigle, CPA
Board Observer, Director, Investissement Québec
Our Science
Our scientists leverage decades of experience in developing small molecule GPCR modulators to address inflammatory-driven conditions that meet three criteria:
1
Target receptors drive the severity of the selected medical condition, the disease progression or low survival rates
2
Medical condition remains an unmet medical need and has a clear regulatory pathway
3
In gold standard preclinical models, our lead drug candidates appear superior to other products used today, or that are in development.
Fibrosis Reduction & Metabolic Regulation: A Balancing Act
Balance between GPR84 and GPR40 plays a significant role in the modulation of the fibrotic and metabolic processes.
Our library of small molecule modulators allows us to re-establish a more favourable GPR84 / GPR40 balance.
Our Lead Product: ING-006
Idiopathic Pulmonary Fibrosis (IPF) affects approximately 140,000 adults in the USA alone, nearly 3 million worldwide.
While the exact cause of IPF remains unknown, repeated injuries to lung cells induce abnormal wound healing processes and life-threatening lung scarring.
IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only 3 to 5 years after diagnosis.
Our Pipeline
